KZIA today
$7.43+$0.03 (+0.41%)close Nov 11, 2026Trend
DailyDowntrend (confirmed)
4 hourSymmetric Triangle
1 hourSymmetric Triangle
15 minBearish
5 minExpanding
Daily trend turns up above $11.25
Key levels
Resistance$8.38
Resistance$7.69
Support$6.89
Support$6.07
Latest news & SEC filings
NewsKazia Therapeutics receives 2026 BioTech Breakthrough award
AnalystKazia Therapeutics receives bullish analyst coverage initiation
AnalystNeedham starts Kazia Therapeutics coverage with Buy rating and $27 price target
All KZIA news →About Kazia Therapeutics
Kazia Therapeutics is a clinical-stage biotechnology company focused on developing cancer therapies. Its lead drug candidates are paxalisib, which acts on a cell-signaling pathway involved in tumor growth, and EVT801, which targets a receptor tied to blood vessel formation in tumors. The company operates in Australia and the United States, running clinical trials and licensing its drug candidates to partners.
Based on the company's 20-F filed Nov 7, 2025.
Nasdaq · Healthcare
KAZIA THERAPEUTICS LTD (KZIA)
What Is the Price Target for KZIA?
SEPT Low Target
$30.60
SEPT Mid Target
$36.00
SEPT High Target
$41.40
Analyst Consensus
$36.00
Is KZIA a Buy or Sell Right Now?
Thesis
- •Revenue growing -98.2% YoY with STRONG trend — consistent growth.
- •SEC filings signal active product innovation — 1 new product/expansion keywords detected in 10-K. R&D investment stable.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for KZIA.
Start Free Trial →Is KZIA Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
PEG, Analyst Consensus
Fair Value
$27.34
42
Moat Score
NARROW
2/9
Piotroski Score
-40.3
Altman Z-Score
What Is Smart Money Doing with KZIA?
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
ACCUMULATING
Short Squeeze Risk
LOW
Signal: NEUTRAL
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →KZIA Growth Story
Revenue YoY
-98.2%
3yr Revenue CAGR
61.3%
EPS Growth YoY
65.64%
FCF Growth YoY
-38.6%
Revenue Trend
STRONG
Dark Pool Trades for KZIA
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for KZIA, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 20:59:33 | $7.44 | 1,400 | $$10K | BUY |
| 20:57:45 | $7.46 | 1,680 | $$13K | BUY |
| 20:16:27 | $7.50 | 6,000 | $$45K | BUY |
| 20:15:55 | $7.37 | 6,000 | $$44K | SELL |
| 20:02:28 | $7.55 | 4,882 | $$37K | BUY |
5 dark pool trades shown · $$149K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for KAZIA THERAPEUTICS LTD (KZIA) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →KZIA — frequently asked questions
What is KZIA stock price today?
KAZIA THERAPEUTICS LTD (KZIA) is at $7.43, up 0.41% (+$0.03) at the Nov 11, 2026 close.
Why is KZIA stock moving today?
Latest KZIA news — Nov 6, 2026: Kazia Therapeutics receives 2026 BioTech Breakthrough award · Oct 30, 2026: Kazia Therapeutics receives bullish analyst coverage initiation
What is the KZIA price target?
The average analyst price target for KZIA is $36.00, ranging from $29 to $40, based on 4 analysts.
What do analysts rate KZIA?
Analyst ratings for KZIA: 0 Buy, 6 Hold, 0 Sell — consensus Hold.
Did KZIA beat earnings?
KZIA last reported on Sep 4, 2026: EPS -$0.60 vs -$0.61 expected — a beat of 0.9%.
Does KZIA pay a dividend?
KZIA does not currently pay a dividend.
How much debt does KZIA have?
KAZIA THERAPEUTICS LTD reported $0M of debt and $4M of cash (Jun 30, 2025).
What are KZIA support and resistance levels?
Support: $6.89, $6.07, $4.86. Resistance: $7.69, $8.38, $9.10.
What are insiders doing with KZIA?
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
What is the latest news on KZIA?
Nov 6, 2026: Kazia Therapeutics receives 2026 BioTech Breakthrough award · Oct 30, 2026: Kazia Therapeutics receives bullish analyst coverage initiation · Oct 30, 2026: Needham starts Kazia Therapeutics coverage with Buy rating and $27 price target